• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » The Strange Side of Antidepressants

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

The Strange Side of Antidepressants

Fun facts from the upcoming Medication Fact Book, 8th Edition

May 23, 2025
Daniel Carlat, MD
StrangeAntidepressants.jpeg

Talia Puzantian and I are in the thick of revising the Medication Fact Book, 8th edition—slated for release this fall.

I’m currently working on the antidepressants chapter, and one of our favorite parts of the book is adding “fun facts” to the end of each medication.

They’re strange, surprising, and oddly memorable.

Here are a few that stood out:

Selegiline (Emsam)

Emsam was named after “Emily” and “Samuel,” the children of the Somerset Pharmaceuticals CEO. It remains the only FDA-approved transdermal antidepressant.

Ketamine

Ketamine was introduced in the 1960s as a safe anesthetic that preserved breathing and blood pressure. During the Vietnam War, U.S. soldiers carried ketamine as a “buddy drug” to administer while awaiting medevac—underscoring its importance in battlefield medicine.

Vilazodone

The brand name “Viibryd” likely has two origins. First, it rhymes with “hybrid,” and the mechanism of action is a hybrid of SSRI and 5-HT1A partial agonism. Second, the word calls to mind “virile,” which could be a subliminal suggestion that it does not worsen sexual functioning.

MAOIs

MAOIs were the first antidepressants developed, after tuberculosis patients given the antibacterial agent isoniazid (INH) were found to have an elevated mood. Isoniazid was found to be an MAOI and was developed as the first antidepressant in the late 1950s.

Paroxetine

In 2012, GlaxoSmithKline was fined $3 billion for promoting paroxetine in children based on misleading data from Study 329. New Scientist later wrote: “You may never have heard of it, but Study 329 changed medicine.”

More to come. Psychiatry is full of these strange little side trails—and we’re trying to follow as many as we can.

Discussion Prompt

  • Have a favorite psych med origin story or oddity?
  • Join the conversation on LinkedIn with Dr. Carlat 
  • Follow for evidence-based skepticism in psychiatry

Share this with someone who appreciates psychiatry’s weird backstories.
Follow me (Daniel Carlat) for more behind-the-scenes notes as we wrap the Med Fact Book, 8th edition.

Related Articles

  • Should You Test MTHFR? (Carlat Psychiatry Podcast) with Chris Aiken, MD, and Kellie Newsome, PMHNP
  • Treating Depression Collaboratively (Webinar) with Garret Rossi, MD
  • Some Antidepressants May Help Longer Than Others with Jeremy Mills, DNP, PMHNP-BC
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.